{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-008482","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.356992+00:00","generated_at":"2026-05-15T10:47:06.317709+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Clene enters third-year NIH subaward with NYU for up to $8M for ALS expanded access program","bullets":["Third-year subaward under $45.1M NIH grant; up to $8M for period 9/1/2025–8/31/2026.","Funds support Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS).","Subaward with New York University as prime awardee; replaces prior subaward with Columbia University for first two years.","Either party may terminate with 30 days' notice; Company retains Background IP and no licenses granted to NYU or US Gov."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-008482","json":"https://secwatch.observer/filing/0001437749-26-008482.json","markdown":"https://secwatch.observer/filing/0001437749-26-008482.md","text":"https://secwatch.observer/filing/0001437749-26-008482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/0001437749-26-008482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/clnn20260316_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:47:06.317709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8ed1f1a024910c69d2c824571f1203840b2b829","claim":"Clene Inc. entered into Year 3 Subaward with New York University (NYU) valued at up to $8.0 million (effective 2026-03-13).","evidence_excerpt":"On March 13, 2026, the Company entered into a subaward agreement for the third year of the NIH Grant with New York University (“NYU”), the prime awardee, for up to $8.0 million during the period from September 1, 2025 to August 31, 2026 (the “Year 3 Subaward”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/0001437749-26-008482-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"New York University (NYU)"},{"label":"Value","value":"up to $8.0 million"},{"label":"Effective","value":"2026-03-13"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}